We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter Issues Recall Notice for Permanent Removal of Life2000 Ventilation
Read MoreHide Full Article
Key Takeaways
BAX is permanently removing the Life2000 ventilation system after identifying a serious cybersecurity issue.
The flaw in BAX's Life2000 could let unauthorized users alter data or therapy settings, risking failure.
BAX reports no serious injuries but urges patients and facilities to stop using Life2000 units immediately.
Baxter (BAX - Free Report) has issued a recall for its Life2000 Ventilation System due to a cybersecurity issue discovered through internal testing, per this FDA notice. The recall has been identified by the FDA as the most serious type, which may cause serious injury or death if you continue to use it. The system is part of the company’s Front-line care segment.
Per the recall alert, Baxter has advised users to stop using Life2000 ventilators and has permanently removed them from the market. Baxter’s latest recall notice follows two earlier recalls for the Life2000 ventilation system issued in 2024 and 2023, related to battery-charging issues and potential oxygen-desaturation risks, respectively.
Baxter added the Life2000 Ventilation System to its portfolio through the acquisition of Hillrom in 2021. The system is intended to provide continuous or intermittent breathing support for individuals who require mechanical ventilation assistance, particularly adult patients who need positive-pressure ventilation delivered through an endotracheal tube or a mask. The system consists of the Life2000 Ventilator and the Life2000 Compressor, and it can be used in home or institutional settings but is not intended for use in ambulances or air transportation.
BAX’s Share Price Performance
Although Baxter is permanently withdrawing the Life2000 Ventilation system, its share price has gained 0.9% since the FDA notice issued on Nov. 26. The contrasting move in the share price is likely due to the fact that the system contributed only a negligible portion of Baxter’s total sales. However, such recalls can potentially have an unfavorable impact on the company’s goodwill.
So far this year, Baxter stock has declined 34.6% against the industry’s gain of 4.9%. The S&P 500 Index has risen 18.9% in the same time period.
Image Source: Zacks Investment Research
More on the Recall
Baxter identified a serious cybersecurity issue with the Life2000 Ventilation System that could allow an unauthorized person to access data or change therapy settings. Such changes could cause the life-supporting air-delivery function to fail to operate as intended. As of April 10, 2025, Baxter has reported no serious injuries or deaths associated with this issue.
The company has recommended that home users discuss therapy-replacement options with their healthcare providers and transfer their care to an alternative medical equipment supplier. It has also advised healthcare facilities to discontinue the use of all Life2000 ventilators and compressors within their operations.
Some better-ranked stocks in the broader medical space areBoston Scientific Corporation (BSX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cardinal Health (CAH - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.36%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 13.7% compared with the industry’s 5.8% growth so far this year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.12%.
IDEXX’s shares have gained 82.1% compared with the industry’s 5.8% gain so far this year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.36%.
Cardinal Health has rallied 79.5% compared with the industry’s 15.6% gain so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter Issues Recall Notice for Permanent Removal of Life2000 Ventilation
Key Takeaways
Baxter (BAX - Free Report) has issued a recall for its Life2000 Ventilation System due to a cybersecurity issue discovered through internal testing, per this FDA notice. The recall has been identified by the FDA as the most serious type, which may cause serious injury or death if you continue to use it. The system is part of the company’s Front-line care segment.
Per the recall alert, Baxter has advised users to stop using Life2000 ventilators and has permanently removed them from the market. Baxter’s latest recall notice follows two earlier recalls for the Life2000 ventilation system issued in 2024 and 2023, related to battery-charging issues and potential oxygen-desaturation risks, respectively.
Baxter added the Life2000 Ventilation System to its portfolio through the acquisition of Hillrom in 2021. The system is intended to provide continuous or intermittent breathing support for individuals who require mechanical ventilation assistance, particularly adult patients who need positive-pressure ventilation delivered through an endotracheal tube or a mask. The system consists of the Life2000 Ventilator and the Life2000 Compressor, and it can be used in home or institutional settings but is not intended for use in ambulances or air transportation.
BAX’s Share Price Performance
Although Baxter is permanently withdrawing the Life2000 Ventilation system, its share price has gained 0.9% since the FDA notice issued on Nov. 26. The contrasting move in the share price is likely due to the fact that the system contributed only a negligible portion of Baxter’s total sales. However, such recalls can potentially have an unfavorable impact on the company’s goodwill.
So far this year, Baxter stock has declined 34.6% against the industry’s gain of 4.9%. The S&P 500 Index has risen 18.9% in the same time period.
Image Source: Zacks Investment Research
More on the Recall
Baxter identified a serious cybersecurity issue with the Life2000 Ventilation System that could allow an unauthorized person to access data or change therapy settings. Such changes could cause the life-supporting air-delivery function to fail to operate as intended. As of April 10, 2025, Baxter has reported no serious injuries or deaths associated with this issue.
The company has recommended that home users discuss therapy-replacement options with their healthcare providers and transfer their care to an alternative medical equipment supplier. It has also advised healthcare facilities to discontinue the use of all Life2000 ventilators and compressors within their operations.
Baxter International Inc. Price
Baxter International Inc. price | Baxter International Inc. Quote
BAX’s Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space areBoston Scientific Corporation (BSX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cardinal Health (CAH - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.36%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 13.7% compared with the industry’s 5.8% growth so far this year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.12%.
IDEXX’s shares have gained 82.1% compared with the industry’s 5.8% gain so far this year.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.36%.
Cardinal Health has rallied 79.5% compared with the industry’s 15.6% gain so far this year.